Clinitech Laboratory Ltd (CTLLAB) is currently trading at 30.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Clinitech Laboratory Limited is a provider of diagnostic and healthcare tests and services through a chain of 8 diagnostic centers around Thane, Raigad, and Navi Mumbai. The company performs over 300,000 tests annually, including a wide range of laboratory diagnostics like biochemistry, immunology, and molecular biology in NABL-accredited labs. Clinitech recently changed its status to a public limited company and has announced an initial public offering (IPO) to raise Rs 5.79 Crores by issuing new equity shares. The company has consistently expanded its diagnostic capabilities, adding new labs in regions like Kalyan and Thane over the past decade to cater to growing demand. Incorporated on March 19, 2010, Clinitech benefits from its promoters' 30+ years of experience in the diagnostic business, contributing to its strong regional reputation.

Over the past 52 weeks, Clinitech Laboratory Ltd has traded between a low of ₹28.55 and a high of ₹47.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Clinitech Laboratory Ltd has a market capitalization of approximately 6.85. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Clinitech Laboratory Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.31 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6.85 Cr, Clinitech Laboratory Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Clinitech Laboratory Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Clinitech Laboratory Ltd is 16.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Clinitech reported consolidated revenue from operations of Rs 9.42 crore for the half year ended September 30, 2026. This was 85.5% higher than Rs 5.08 crore in the corresponding September 2025 half-year. Total income was Rs 9.45 crore, including Rs 2.79 lakh of other income.

Clinitech Laboratory reported standalone profit after tax of Rs 24.46 lakh for the half year ended September 30, 2026. This was Rs 5.57 lakh below the Rs 30.03 lakh reported in the half year ended September 30, 2025.

Clinitech Laboratory's board meeting is scheduled for November 13, 2026, at 12:00 noon IST. The meeting will be conducted through video conferencing.

A board meeting was held on February 06, 2026, and it ran from 03:00 PM IST to 03:20 PM IST, with a disclosed duration of 20 minutes.